Pharma Marketing Across the Product Lifecycle

A brand plan that looks the same in year two and year eight is a sign that nobody asked what stage the product is in. The audiences, the message, the channels, and the right amount of money all change as a drug moves from new to familiar to facing generic or biosimilar competition. This article lays out those shifts and gives an illustrative allocation for each stage.

The four stages of the pharma product lifecycle

Each stage has a different commercial question:

• Launch (roughly year 0 to 2). Will the right prescribers try it?
• Growth (roughly year 2 to 5). Can we expand to more prescribers, patients, and indications?
• Maturity (roughly year 5 to LOE minus 2). Can we hold share and keep patients on therapy efficiently?
• Loss of exclusivity (LOE minus 2 to after entry). How do we manage the decline and protect what is still protected?

The years are illustrative. Exclusivity periods vary a great deal by product, patents, and litigation, and a new indication can restart a growth phase in the middle of maturity.

How audiences change by stage

At launch, the audience is small and specific: the prescribers most likely to try a new therapy for the right patients. The drug launch media plan covers this in detail. During growth, the target list widens to mid-potential prescribers, adjacent specialties, and nurse practitioners and physician assistants. If patients are a real lever, DTC often starts or scales here.

At maturity, most prescribers in the category know the drug. The audience question becomes who is drifting away. That includes physicians whose share is falling and patients who stop treatment. Adherence becomes as important as new starts. Near LOE, the audience narrows again, often to loyal patients, their caregivers, and payers.

How channels and messages shift

An illustrative budget allocation by stage

The table below is hypothetical. It shows the shape of how spending shifts, not a benchmark. Real allocations depend on the category, competitive set, patient population size, and commercial model. Each row is indexed so that the launch-year total equals 100.

A few things to notice. Growth can be the peak year, not launch, because that is when DTC often scales. Patient support holds up longer than any other line because it protects existing patients. At LOE, the total drops to a fraction of launch, and what remains is mostly retention.

For a specialty brand with no DTC, the DTC column would be near zero throughout and field plus HCP media would carry more weight. For the budget mechanics within media, see how to allocate a pharma programmatic budget.

What changes at loss of exclusivity

When generics (for small molecules) or biosimilars (for biologics) enter, most new prescriptions in many categories move to the lower-cost product quickly, often driven by pharmacy substitution rules and payer formularies. Promotion of the brand at that point rarely changes the outcome much. Biologics can hold share longer, because biosimilar substitution and adoption work differently, but planning should assume erosion.

Lifecycle management usually starts years before LOE. New formulations, new indications, or combination products can create protected positions, and the marketing plan has to decide whether to move patients to those before generics arrive. That is a commercial and legal question as much as a media one.

The media team's job near LOE is mostly to cut cleanly. Stop broad media before it becomes waste, keep support programs running, and keep branded search alive so patients searching for the brand still find support resources. Scenario planning helps here, because LOE timing can move with litigation.

What usually goes wrong

1. Launch-level spend held into maturity. The budget stays high because cutting feels like giving up, even when incremental returns have faded.
2. Growth starved. Teams cut after launch and miss the window where expanding to new segments would pay off most.
3. Adherence ignored. Mature brands keep chasing new starts while existing patients quietly stop refilling.
4. LOE surprise. No plan for which programs to keep, so everything stops at once, including patient support.

Practical takeaway

Write down which lifecycle stage your brand is in and the main commercial question for that stage. Then ask if your largest budget line answers that question. If you are mature and the largest line is still a launch-style awareness channel, start building the case for reallocation using the framework in pharmaceutical marketing strategies.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.